FDA Commissioner Raises Concerns With the Incentives in the Orphan Drug Act
While the development of orphan drugs for rare diseases has skyrocketed in the last 30 years, Dr. Scott Gottlieb, Commissioner of the Food and Drug Administration is recently questioning the…